Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

33%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 2Efficacy & side effects

1(50.0%)

N/ANon-phased studies

1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Other(1)

Detailed Status

unknown1

Completed1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 21 (50.0%)

N/A1 (50.0%)

Trials by Status

unknown133%

completed133%

not_yet_recruiting133%

Recent Activity

0 active trials

Showing 3 of 3

not_yet_recruitingphase_2

Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer

NCT07018063

completed

Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China

NCT06869356

unknownnot_applicable

D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma

NCT03051152

Clinical Trials (3)

Showing 3 of 3 trials

NCT07018063Phase 2

Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer

Not Yet Recruiting

NCT06869356

Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China

Completed

NCT03051152Not Applicable

D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma

Unknown

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3